These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 19717225)
21. Targeting the PI3K-AKT-mTOR Pathway in Castration Resistant Prostate Cancer: A Review Article. Cham J; Venkateswaran AR; Bhangoo M Clin Genitourin Cancer; 2021 Dec; 19(6):563.e1-563.e7. PubMed ID: 34433523 [TBL] [Abstract][Full Text] [Related]
22. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Newton HB Expert Rev Anticancer Ther; 2004 Feb; 4(1):105-28. PubMed ID: 14748662 [TBL] [Abstract][Full Text] [Related]
29. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080 [TBL] [Abstract][Full Text] [Related]
30. PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Chang L; Graham PH; Hao J; Ni J; Bucci J; Cozzi PJ; Kearsley JH; Li Y Cell Death Dis; 2014 Oct; 5(10):e1437. PubMed ID: 25275598 [TBL] [Abstract][Full Text] [Related]
31. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells. Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210 [TBL] [Abstract][Full Text] [Related]
32. Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target? Braglia L; Zavatti M; Vinceti M; Martelli AM; Marmiroli S Biochim Biophys Acta Mol Cell Res; 2020 Sep; 1867(9):118731. PubMed ID: 32360668 [TBL] [Abstract][Full Text] [Related]
34. Isorhamnetin inhibited the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the mitochondrion-dependent intrinsic apoptotic and PI3K/Akt/mTOR pathway. Cai F; Zhang Y; Li J; Huang S; Gao R Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32039440 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer. Shiota M; Bishop JL; Takeuchi A; Nip KM; Cordonnier T; Beraldi E; Kuruma H; Gleave ME; Zoubeidi A Oncotarget; 2015 Apr; 6(11):9086-98. PubMed ID: 25871401 [TBL] [Abstract][Full Text] [Related]
37. New drug development in metastatic prostate cancer. Armstrong AJ; George DJ Urol Oncol; 2008; 26(4):430-7. PubMed ID: 18593623 [TBL] [Abstract][Full Text] [Related]
38. Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy. Wu J; Yu E Cancer Metastasis Rev; 2014 Sep; 33(2-3):607-17. PubMed ID: 24414227 [TBL] [Abstract][Full Text] [Related]
39. Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway. Hixon ML; Paccagnella L; Millham R; Perez-Olle R; Gualberto A Rev Recent Clin Trials; 2010 Sep; 5(3):189-208. PubMed ID: 20533896 [TBL] [Abstract][Full Text] [Related]
40. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Ghayad SE; Cohen PA Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):29-57. PubMed ID: 19751211 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]